Welcome to our dedicated page for Protagonist Therapeutics SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Protagonist Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Protagonist Therapeutics's regulatory disclosures and financial reporting.
PTGX reported a Form 144 notice indicating proposed sales of 12,000 shares of Common Stock. The filing lists two compensation-related lots of Common stock — 10,000 shares dated 05/16/2018 and 2,000 shares dated 12/03/2019. The form shows a value figure of $1,200,873.60 and an entry 05/07/2026 associated with the NASDAQ listing.
Protagonist Therapeutics reported a profitable first quarter of 2026 driven by collaboration milestones and a strong cash position. License and collaboration revenue reached $56.4 million, nearly doubling from the prior year period, mainly from a $50.0 million FDA-approval milestone for ICOTYDE, its oral psoriasis drug partnered with JNJ.
The company generated net income of $3.8 million, compared with a loss of $11.7 million a year earlier, as milestone revenue more than offset higher research and development spending of $46.7 million. General and administrative expenses rose to $13.3 million, reflecting headcount and stock-based compensation growth.
Cash, cash equivalents and marketable securities totaled about $620.3 million at March 31, 2026, providing substantial funding for its pipeline in inflammation, hematology and metabolic diseases. After quarter-end, Protagonist exercised its opt-out right in the Takeda rusfertide deal, triggering a $200.0 million payment and shifting the arrangement to a global royalty and milestone model.
Protagonist Therapeutics posted a profitable first quarter of 2026 while securing major regulatory and partnership milestones. License and collaboration revenue reached $56.4 million, up from $28.3 million a year earlier, driving net income of $3.8 million versus a prior-period net loss of $11.7 million.
ICOTYDE received U.S. FDA approval for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment and positioning Protagonist to earn up to $580 million more in milestones plus 6%–10% tiered royalties. Rusfertide’s NDA was accepted with Priority Review and a PDUFA goal date in August 2026.
By opting out of the U.S. profit and loss sharing with Takeda for rusfertide, Protagonist unlocked a $200 million payment, with eligibility for an additional $200 million opt-out fee, a $75 million approval milestone, and up to $775 million in sales milestones, alongside 14%–29% worldwide royalties. Cash, cash equivalents and marketable securities totaled $620 million as of March 31, 2026, which the company expects to fund operations through at least 2028.
Vanguard Capital Management reports beneficial ownership of 3,250,003 shares of Protagonist Therapeutics Common Stock, representing 5.09% of the class. The filing states Vanguard has sole power to dispose of 3,250,003 shares and sole voting power for 444,107 shares. The statement is signed on 04/30/2026.
Protagonist Therapeutics Inc Schedule 13G filing reports that Vanguard Portfolio Management beneficially owned 3,533,015 shares of Common Stock, representing 5.53% of the class as of 03/31/2026. The filer states sole dispositive power over the 3,533,015 shares and sole voting power for 51,804 shares. The filing is signed on 04/29/2026 by a Vanguard official.
Protagonist Therapeutics plans a virtual 2026 annual stockholder meeting on June 17, 2026 at 10:00 a.m. Pacific Time. Holders of 64,305,185 common shares as of April 22, 2026 may vote.
Stockholders will elect two Class I directors, approve an advisory say‑on‑pay vote, ratify Ernst & Young LLP as 2026 auditor, and vote on adopting a 2026 Equity Incentive Plan. The new plan would draw on 3,352,115 shares remaining under the 2016 plan as of March 31, 2026, add 650,000 new shares, and later recycle certain forfeited awards, supporting continued equity‑based compensation for employees, executives and directors.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel, Ph.D. reported a bona fide gift of 1,460 shares of Common Stock to family and friends. The transaction carried a reported price of $0.00 per share, reflecting that no sale proceeds were received.
Following this gift transfer, Patel directly holds 523,478 shares of Protagonist Therapeutics Common Stock. The filing shows no option exercises or open-market purchases or sales in this transaction, only the non-cash gift disposition.
Protagonist Therapeutics Chief Financial Officer Ali Asif reported an open-market sale of 1,750 shares of common stock at $105.47 per share on April 20, 2026. According to the filing, the sale was made to cover tax withholding obligations triggered by the settlement of restricted stock units.
After this transaction, Asif directly holds 59,003 shares of Protagonist Therapeutics common stock, indicating that the sale represents a small portion of his overall reported holdings.
PTGX Form 144 notice reporting a proposed sale of 1,750 shares of Common Stock tied to restricted stock vesting on 04/20/2026. The filing also lists recent dispositions by a holder: 46,203 shares on 01/27/2026 and 24,765 shares on 03/26/2026.